Related Experiment Video

Updated: Aug 20, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K

Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of

Vivian Petersen Wagner1, Renata Ferrarotto2, Pablo Agustin Vargas3

  • 1Academic Unit of Oral and Maxillofacial Medicine and Pathology, Department of Clinical Dentistry, University of Sheffield, Sheffield, UK.

Critical Reviews in Oncology/Hematology
|November 25, 2022
PubMed

Insights

No FDA-approved drugs exist for adenoid cystic carcinoma (ACC) systemic therapy. Clinical trials primarily focus on advanced ACC, with small-molecule inhibitors like Apatinib showing modest efficacy, necessitating further research.

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Adenoid cystic carcinoma (ACC) lacks FDA-approved systemic therapies.
  • A significant patient population requires effective treatment options.

Purpose of the Study:

  • To review clinical trials for drug-based therapies in ACC.
  • To identify promising agents and challenges in ACC treatment development.

Main Methods:

  • Systematic review of ACC clinical trials registered on ClinicalTrials.gov.
  • Analysis of 33 drug-based therapy trials, predominantly Phase II, single-arm studies.
  • Evaluation of inclusion criteria and investigated drug classes.

Main Results:

  • Small-molecule inhibitors were the most studied drug class.
  • Apatinib, Axitinib, and Lenvatinib demonstrated notable efficacy under strict enrollment criteria.
  • Median time to progression remains modest, indicating a need for improved therapies.

Conclusions:

  • Current ACC clinical trials focus on advanced disease with limited success in improving progression times.
  • Targeting key pathways in ACC aggressiveness shows promise, pending efficacy proof.
  • Further research and development of novel systemic therapies are urgently required.
Keywords:
ChemotherapyHead and neck cancerOncologySalivary gland cancer

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
637
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.7K